patent

Acelrx Pharmaceuticals Inc

deal

$ACRX so they make a deal (give away the drug for nothing)and don’t have the BBB alls to do a cc to explain.

Main risks would be continued delays or underwhelming deal for DSUVIA, lack of US Army orders, and any delays/setbacks to EUA for NIYAD.

SHIT COMPANY MANAGEMENT  TELLING STORIES ABOUT PARTNERSHIP AND LICENSE DEAL SINCE 2018, BUT NOTHING MATERIALIZED.

NO PARTNERSHIP LICENSING DEALS, SHIT COMPANY MANAGEMENT KEEPS ON TELLING STORIES SINCE 2018.

By them pushing the deal so far back it hints to me that they don’t truly plan to make any money next year as there is no concern for saving money on taxes, either that or there is no upfront or it’s minuscule

But of course, they were silent about the details of such deal.

revenue

Terrible management 
No execution of good drug revenue plan and we all lost our all money here
I lost most here too
I will never invest in bio or drug related stock which requires FDA approval 
All scam and fraud mostly
90% bio.

SHIT COMPANY MANAGEMENT KEEPS ON TELLING STORIES ABOUT PARTNERSHIP SINCE 2018 TILL TO DATE NOTHING MATERIALIZED AND NO REVENUE.

Negative REVENUE (not sure how you do that) reported this morning.

Spending more than revenue is not financial results it&#39;s lack of financial results.

but bad managment you would think with such a good drug they could have done better but vince felt the need to keep paying him and his team ridiculous weekly salarys without any revenues to cover sorry acrx my funds will no longer be kept here.

PFS-01 &amp; 02          
-  &quot;exceeds $100 million&quot;          
-  &quot;Perioperative medication errors.

patient

-  Frequent blood draws to measure calcium  
are time-consuming and expensive 
-   Even more complicated in patients with liver failure

$ACRX  Sad for Lupus patients, which is very painful too!

The flow rates used to clear waste products and remove fluid from the patient are very fast, potentially putting stress on a patient’s heart and blood pressure.

-  Even more complicated in patients with liver failure    
    
Heparin    
-  Significant safety concern for patients at risk of bleeding.

-  Even more complicated in patients with liver failure 
 
Heparin 
-  Significant safety concern for patients at risk of bleeding 
-  Clinicians fear over anticoagulating the patient 
-  Etc.

Prognosis for patients with ARDS is generally poor and varies based on the severity of illness, the precipitating insult, and medical comorbidities.

Any ideas what’s holding them up on saving their clients money and providing their patients the best in class anesthesia?

executive

I fail to find the right words to describe how pathetic this guy is. CEO?

$ACRX 
So I guess HC Wainwright’s has taken the role of CFO and Rafi has taken the role of CEO…..  WTF is goin’ on over there?!

$ACRX 
Never thought that I will lose all my money here
CEO CFO should deserve to be fire

And we are just thrilled to move this forward and really help these patients out, hopefully with that EUA

And we are just thrilled to move this forward and really help these patients out, hopefully with that EUA.

Niydad might be a tasty accretive buy, with EUA likely in 2023, etc.

And we are just thrilled to move this forward and really help these patients out, hopefully with that EUA (Emergency Use Authorization).

quot

$ACRX  
 
12/29/23 - 3rd Qtr ER  
 
&quot;Vincent Angotti: Thank you, Raffi.

Just MAZIMIZE shareholder value, so do it right! &quot;.

$ACRX The FDA will be pleased with AcelRx &quot;growing database supporting the benefits of DSUVIA-DZUVEO!

&quot;We&#39;re excited to now have DZUVEO as part of our product portfolio available to our existing customers.

product

$ACRX AcelRx has some GREAT EMA &amp; FDA approved products, and I like the potential of Niyad!

$ACRX Battlefield Pain Management 
Our new products meet these requirements and add to the pain-treatment options available to care providers.

It allows doctors to give patients the fluids, nutrition, antibiotics and other medications they need without worrying about the accumulation of waste products and fluid from the failing kidneys.

$ACRX here, let me sum it all up:  Dsuvia=great idea, and a good product.

The slow and continuous nature of the process, typically performed over a 24-hour period, allows patients with unstable blood pressure and heart rates, which is termed hemodynamically unstable, to better tolerate this process.

InflaRx N.V.

covid

Makes one wonder what frame of reference is being used to label this pandemic over: seems to me that the pandemic of hyperinflammation continues to rage, and getting worse.

$IFRX Sadly 2.3k deaths this past week were recorded in Japan attributable to covid, following last week’s previous record of 2.2k deaths, despite overwhelming prevention through antivirals, unlike China’s prevention approach.

$IFRX after 2 years of this pandemic it has now hit me too, yesterday I had severe flu-like symptoms and today severe coughing phlegm.

The perfect dream scenario would be to get a Covid EUA and then a Mrk shocker for the onc world!

$IFRX C&#39;mon - EUA imminent 🚀 🚀 🚀 🚀 🚀 🚀 🚀 💪

$XBI Come to where the flavor is, come to $IFRX ❤️ EUA imminent 👌

May your heart be warmed by the sweet magic that Christmas always brings, and may all your dreams be fulfilled, EUA for example 🎄

$IFRX FANT‼️‼️ EUA approval any moment now.

$IFRX This is great that we have already much more attention, once EUA arrive the stock will explode to minimum 5$ 
 
🚀🚀🚀🚀🚀🚀🚀

Thank you InflaRx for your Protective Foundation and global patents.

In the global market desperate for biotech to address broken immune systems by way of controlling inflammation, InflaRx has a game changing winner in vilo, worthy of all those global patents.

news

$IFRX News this week 🤞🤞🤞😁😁😁

$IFRX good news   ed got the short shares covered 
 
https://iborrowdesk.com/report/IFRX

$IFRX FANNY 🚀🚀 
 
FAntastic 
News on 
New  
Year

Upside: further good news from China and approval.

Premarket stock gainers on news and/or vol.

application

$IFRX we should get year end report late march   if we have nothing from fda, ema or china we can only hope for cancer trial because pg is 2 years and an offering(s)  away       I’m a bull with alot of shares

$IFRX FDA approve now..vilo works and is safe!

Many options, FDA, NMPA and EMA. 🚀🚀🚀🤞🤞

I like Ifx-1’s chances of fda approval.

approval

PG treated with 2400mg/vilo is the strongest indication yet of vilo’s effectiveness =  approval.

An approval would give it backbone, and further approvals will give it explosive growth.

$IFRX Vilo approval during Green Week, the stuff of poetry.

$IFRX nice to see us finally moving   an extra 2.5 mil is nice should have our cash at least 93 mil with no debt   with ema approval we will tap those final  funds from german government and fda approval should hopefully send us into orbit

Approvals &amp; encouragements are lining up nicely with the pipeline.

$IFRX Monday is a good day for approvals - FANM 🤞🤞🤞🤞

Edesa Biotech Inc

A company to lose close to 25% in 3 days on no news shows Gary is absolutely USELESS.

$EDSA Whatever the news is (that somehow got leaked and is responsible for this going up more than 100% in a week) once it is properly announced I will GTFO and never come back to this Indian scammer Pars POS stock.

but watching APVO today is not very comforting for when we release news.

$EDSA These shitheads aren’t sharing the good news.

I simply want to see Edesa Biotech management try to put out any positive news release during this year and then realize that their news release once again had the opposite effect in moving the share price down another 41%+ during that day.

40-50% crushed on good news and then no rallies at all.

rate

Patients with rapidly improving ARDS still had a 55% mortality rate, much higher than earlier reported.

but embarrassingly, the FDA isn&#39;t impressed with an 84% death reduction rate? WTF?

3) QUESTIONABLE TRIAL GROUP - High placebo mortality rate and wide variance of dosed patients (L4 - L6) make it impossible to know what patient exactly should receive the  drug in Emergency Use, hence why they would like to see another trial.

Lowers the body temperature almost immediately, almost at an disturbing rate.

Short Borrow Fee rate has increased from approx 6% to 8% !!!!

Still don’t think it deserved an 8k when we can’t even get main asset trial approval prs for years.

but it scares the shite out of me that the FDA has not approved our trial in over a year.

but starting phase 3 sometime this year, eb05 in trials and asking for fda phase 3 approval in numerous USA sites, just announced a EB06 trial starting in Canada and eb07 coming soon this would have to be the most idiotic bio company in Canadian history.

$EDSA they have 2 products, both of which are not FDA approved.

It seems a wee bit like some kind of half broken pump which had been purchased from a  bargain basement or fire sale clearance kind of vendor or a PUMP which would be purchased from some gold caps toothed Tamil Sri Lankan, lol.

1) Phase 3 FDA approval is imminent as it makes no sense for them to acknowledge the need for this drug and not be more flexible with the trial protocol.

The only reason VERU did not get EUA approval was due to a weak safety profile.

And the pipeline chart on website is so misleading cuz our P3 protocol is even not yet approved by FDA

business-result

$EDSA 

EBO1 Stat Sig results

Reached Primary Endpoint 

Dropped 44%? WTF?

$EDSA disappointing management hasn’t come out defending the EB01 results.

$EDSA long time bulls like Mr. Bitcoins are leaving forever after these terrible EB01 allergic contact dermatitis results … it’s over sad to say … at least the company tried their best,

But, let me tell you why the Bulls have disappointed me - nobody seemed able to defend these top line results and the Bears for being stupid lucky.

$EDSA Results were not good and even more concerning was that the higher regarded 2% dose showed nothing.

There may be potential to improve the results further.

but they can pass on their illness to others and, as a result, you need to protect yourself from them.

The delay is merely serving long ago determined intents on the part of this fack named Par and his fellow Edesa Biotech accomplices; and we may be losing just shy of every single penny we place here with Edesa Biotech Inc as a result.

Edessa is dead and her CEO is a swindler.

Wouldn’t it be great if the CEO could even spare 1 hour every quarter to write a shareholder letter…

The CEO adding provides me no solace anymore.

Small buys by the President and CFO, and yet the share price just keeps collapsing.

EUA any day… 
 
So glad I’m not short AND have my biggest position here than EVER  before.

What I love about this stock is the probability of EUA Filing and the fact WE DON&#39;T HAVE TO WAIT FOR FDA APPOVAL IF EU, THE STOCK WILL EXPLODE ON THE FILING ALONE!

8 granted patents Additional pending (5 in the U.S.) patent applications 
(Europe, China Japan and more) 
$3+ short term 
ATH $10+ longterm 
 
$EDSA Its truly powerful how it is holding all of its gains and bracing for the next leg up.

but my god everything has aligned for some very very very good news

$EDSA Not a single negative news about this stock and yet the price is falling .

$EDSA friends 
 
Great news 
 
In 2027 we might reach a profit 
 
Hahahahahahahahahaha

company

but I like what the company is trying to do/develop and the good it would do if successful.

$EDSA multiple billion dollar company. 🤦‍♀️

but this company never ceases to disappoint.

$EDSA Pretty pretty pretty neat  that myself and 3 other retail I know own around 5% of this company.

But, I do think good things are coming the way of this company before June.

$EDSA I’m literally so feed up with this company and stock.

One thing you have to give props to this company is their management of cash.

volume

$EDSA -9% on 50k volume is an astonishing accomplishment.

Short volume Ratio for last EIGHT straight trading days is averaging about 60%+

🧐

$EDSA last night&#39;s close was a very good close with very good share volume

however what we can see, apart from all our assumptions about it, right or wrong, the volumes are high compared to the previous months, which means a lot of interest in the title

$EDSA Reasonable volume everyday since 12/20.

$EDSA good volume today 1.5 of average 
We are on the right path

then news..then some real volume..up up and away

$EDSA the fact that this rise has been steady and medium volume is a good thing.

ACRX

Acelrx Pharmaceuticals Inc

-66.25%

$2.03 - $0.69

Jan, 18, 2023

Jan, 10, 2023

IFRX

InflaRx N.V.

-20.18%

$2.23 - $1.78

Jan, 14, 2023

Dec, 30, 2022

EDSA

Edesa Biotech Inc

-24.09%

$1.37 - $1.04

Jan, 13, 2023

Jan, 12, 2023

ACRX

Acelrx Pharmaceuticals Inc

-66.25%

$2.03 - $0.69

Jan, 18, 2023

Jan, 10, 2023

Jan, 4, 2023

Dec, 6, 2022

Dec, 2, 2022

Nov, 30, 2022

Nov, 28, 2022

Nov, 22, 2022

Nov, 21, 2022

Nov, 21, 2022

IFRX

InflaRx N.V.

-20.18%

$2.23 - $1.78

Jan, 14, 2023

Dec, 30, 2022

Dec, 23, 2022

Dec, 23, 2022

Dec, 22, 2022

Dec, 21, 2022

EDSA

Edesa Biotech Inc

-24.09%

$1.37 - $1.04

Jan, 13, 2023

Jan, 12, 2023

Jan, 11, 2023

Jan, 8, 2023

Dec, 29, 2022

Dec, 22, 2022